Patent application number | Description | Published |
20090253166 | Conjugation of Peptides - Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group. | 10-08-2009 |
20090264366 | Transglutaminase Mediated Conjugation of Peptides - Methods for conjugating peptides are provided comprising i) reacting a peptide with a first compound comprising a functional group in the presence of a transglutaminase capable of incorporating said compound into the peptide to form a transaminated peptide, and ii) reacting said transaminated peptide with e.g. a functionalized polymer capable of reacting with the functional group incorporated in the peptide in the enzymatic reaction. | 10-22-2009 |
20090264435 | Novel Aryl- and Heteroarylpiperazines - Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor. | 10-22-2009 |
20100184641 | Novel Plasma Protein Affinity Tags - Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives. | 07-22-2010 |
20100303786 | Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a R—CHO motif, e.g. Benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, or 5-formyl-4-methylimidazole. | 12-02-2010 |
20110003752 | New Blood Coagulation Factor Inhibitors - The invention relates to novel compounds with formula (I) X | 01-06-2011 |
20130079340 | Benzothiazoles Having Histamine H3 Receptor Activity - Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions. | 03-28-2013 |
20130338394 | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXYMETHYLENE-3 OXO-BUTYRATES - Enolate salts of 4-fluoro-2-hydroxymethylene-3-oxobutyrates of formula wherein R | 12-19-2013 |
Patent application number | Description | Published |
20100303786 | Stabilisation of Liquid-Formulated Factor VII(A) Polypeptides by Aldehyde-Containing Compounds - The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a R—CHO motif, e.g. Benzaldehyde, 3-hydroxybenzaldehyde, 4-hydroxybenzaldehyde, or 5-formyl-4-methylimidazole. | 12-02-2010 |
20110003752 | New Blood Coagulation Factor Inhibitors - The invention relates to novel compounds with formula (I) X | 01-06-2011 |
20110229453 | BLOOD COAGULATION FACTOR INHIBITORS - The invention relates to novel compounds with formula (I) useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives. | 09-22-2011 |